<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04066608</url>
  </required_header>
  <id_info>
    <org_study_id>FLASH</org_study_id>
    <nct_id>NCT04066608</nct_id>
  </id_info>
  <brief_title>Prevalence of Advanced Fibrosis in Patients Living With HIV</brief_title>
  <acronym>FLASH</acronym>
  <official_title>Cross-sectional Study on the Prevalence of Fatty Liver and Metabolic Risk Factors in an HIV-infected Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Monocentric, cross-sectional study to define the prevalence of advanced fibrosis in an HIV
      infected outpatient population
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Globally a shift in the spectrum of diseases has occurred. While in earlier year's infectious
      (communicable) disease were the main contributors to morbidity and mortality, today
      non-communicable diseases (NCD) exhibit a dramatic increase and have reached epidemic
      proportions, even in developing countries. Diabetes, cardiovascular disease, and cancer are
      the most frequent NCDs and the underlying risk factors including Insulin resistance,
      dyslipidemia and obesity have been increasing over the last decades. The current study
      explores the prevalence of advanced fibrosis in an HIV-infected outpatient study population.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Advanced hepatic fibrosis defined by transient elastography using Fibroscan and a cut-off value of &gt;8,6 kPa</measure>
    <time_frame>24 months</time_frame>
    <description>250 patients will be assessed by transient elastography using fibroscan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of hepatic steatosis</measure>
    <time_frame>24 months</time_frame>
    <description>The secondary outcome measure is the prevelance of hepatic steatosis assessed by controlled attenuation parameter (CAP) using Fibroscan with a threshold defined with 248 db/m</description>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Fatty Liver Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Outpatient Study Population at the University Medical Center Mainz
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed consent

          -  age &gt;18

        Exclusion Criteria:

          -  pregnancy

          -  disease with expectation of life under 12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Medical Center of the Johannes Gutenber Univeristy</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 17, 2019</study_first_submitted>
  <study_first_submitted_qc>August 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2019</study_first_posted>
  <last_update_submitted>August 22, 2019</last_update_submitted>
  <last_update_submitted_qc>August 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johannes Gutenberg University Mainz</investigator_affiliation>
    <investigator_full_name>Priv.-Doz. Dr. J. Schattenberg</investigator_full_name>
    <investigator_title>JÃ¶rn Schattenberg, MD; Head of the Metabolic Liver Research Program</investigator_title>
  </responsible_party>
  <keyword>Non-invasive Diagnostics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

